Results 151 to 160 of about 14,564 (189)

Evolution of Anti-Vascular Endothelial Growth Factor Clinical Trial Design for Treating Neovascular Age-Related Macular Degeneration. [PDF]

J Vitreoretin Dis
Klufas MA, Regillo CD, Mandava NK, Miller EG.   +3 more
europepmc   +1 more source

Visual Outcomes Following Infectious Endophthalmitis from Intravitreal Injections of Biologic Drugs: An Intelligent Research in Sight Registry Retrospective Analysis. [PDF]

Ophthalmol Ther
Zhang R, Tunon-Robinson I, Nguyen AK.
europepmc   +1 more source

Efficacy of a single dose switch from aflibercept to ranibizumab in the treatment of neovascular age-related macular degeneration. [PDF]

PLoS One
Iby J, Coulibaly L, Hollaus M, Yeghiazaryan L, Schmidt-Erfurth U, Bühl W, Sacu S.   +6 more
europepmc   +1 more source

Systemic and ocular complications related to intravitreal administration of anti-VEGF agents. [PDF]

Med Hypothesis Discov Innov Ophthalmol
Koksaldi S, Kayabasi M, Karti O, Saatci AO.   +3 more
europepmc   +1 more source

Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion. [PDF]

BMC Ophthalmol
Cho J, Park SM, Kim CG, Kim JH.
europepmc   +1 more source

Shaping the future of retinal care in India: Anti-VEGF therapy now and beyond. [PDF]

Indian J Ophthalmol
Karpe A, Narula R, Shroff D, Roy A.
europepmc   +1 more source

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.

JAMA Ophthalmol
Lee WK, Wong TY, Chen SJ, Sun X, Cheung CMG, Silva R, Ricci F, Zhang X, Machewitz T, Schulze A, Schmidt-Ott UM, Zhao M, Hasanbasic Z, Leal S, Iida T, PULSAR Study Investigators.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aflibercept

Reactions Weekly, 2017
  +8 more sources